An investigational immunomodulator gel significantly improved malodor and measures related to pain and quality of life for ...

The interferon regulatory factor (IRF) family of transcription factors, pivotal for initiating antiviral type I interferon ...

Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...

Shattuck Labs (STTK) pivots from oncology to focus on SL-325 for inflammatory bowel disorders, following underwhelming ...

Dark Blue Therapeutics ("Dark Blue"), a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen (NASDAQ: AMGN).

Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...

Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...

Multiple sclerosis (MS) is a chronic neurological disease characterized by nerve damage and consequent impairments in vision, ...

Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small ...

Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations -- Program will ...

GTB-5550 represents GT Biopharma's third NK cell engager advancing toward clinical development, targeting B7-H3, a protein prevalent across breast, lung, ovarian, pancreatic, prostate, bladder, and ...

Amgen is committed to reducing drug costs, expanding its AmgenNow program, and investing in US manufacturing to gain tariff ...